Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.

Oppenheimer analyst Jay Van Sciver raised Viking Therapeutics' price target to $120, citing strong trial data and an improving probability of success for its key drug.